Management strategies for advanced gastrointestinal stromal tumors after failure of imatinib

苏向前,杨宏

DOI: https://doi.org/10.7504/CJPS.ISSN1005-2208.2015.04.18

2015-01-01

Abstract:Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the digestive tract. Imatinib is presently the standard first-line therapy for patients with metastatic or unresectable GIST. As entering the clinical arena in the last decade, imatinib substantiallyimproved the outcome in the formerly untreatable carcinomas. However, most advanced GIST responding to imatinib will progress within 2-3 years due to heterogeneous subclones harboring a range of imatinib-resistant secondary c-kit mutations. Sunitinib and more recently regorafenib, have obtained US Food and Drug Administration approval for the treatment of GIST after imatinib failure, and thus expanded the treatment options in resistant disease. Patients with metastatic GIST who have focal resistance to tyrosine kinase inhibitor therapy may bene fi t from surgical cytoreduction. Furthermore, surgery may also provide palliation in certain patients with advanced disease who experience intestinal obstruction, perforation or hemorrhage.